D-Galactose

We are D-Galactose CAS:59-23-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Synonyms:
galactos
D-Galactose
D-(+)-Galactose
(+)-galactose
MaltaseHydrate
Dextrogalactose
Cerebrose
Lactoglucose
d-galactos
Gal
brain sugar
D(+)-Glactose
 
Molecular Formula:  C6H12O6
Molecular Weight:  180.15600
 
Appearance and traits: white
Density: 1,5 g/cm3
Boiling point: 410.8ºC at 760 mmHg
Melting point: 168-170 °C(lit.)
Flash point: 202.2ºC
Refractive index: 80 ° (C=10, H2O)
 
Stability: Stable under normal temperatures and pressures.
Storage conditions: Store at RT.
Applications: D-Galactose is a natural hexose, a C-4 epimer of glucose.

Items of Analysis Standard of Analysis Test Results
Appearance White to off-white crystalline powder Conform
Assay ≥99.0% 99.49%
Residue on ignition ≤0.1% 0.062%
Chloride(Cl) ≤0.005% Conform
Specific rotation +78~+81.5 +80.012
Loss on drying ≤1.0%  0.16%
Colonies number (CFU/g) ≤1000 ND
Conclusion Conforms to Factory Standard
 

 

D-Galactose


Related News: An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug.2,2-Dimethyl-1-oxaspiro[2.2]pentan China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.carbonyldi-iodobis[o-phenylenebis(dimethylarsine)]osmium The company’s iPSC product platform unites stem cell biology and precision genetic engineering to create renewable master engineered iPSC lines that can be repeatedly used to mass produce cancer-fighting immune cells, replacing the high production costs, weeks of manufacturing time, and complex engineering processes required for current-generation CAR T-cell immunotherapies with an off-the-shelf product that has the potential to reach many more patients.5-Fluoro-2-methylindole CAS:399-72-4 The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.

Related Products
Product Name
3-dimethoxyphosphoryl-3H-2-benzofuran-1-one View Details
[Chloro(difluoro)methyl](trimethyl)silane Cas:115262-00-5 View Details
1-pentyl-3-methylimidazolium chloride View Details
1-Bromopentane manufacturer Difluoroiodomethane Cas:1493-03-4 manufacturer Trimethylsilyl cyanide manufacturer 4-Chlorobutyl 3,4-dimethoxybenzoate manufacturer Serinol manufacturer